Renewed Canadian Drugs and Substances Strategy (Horizontal initiative)

On this page

General information

Lead department

Health Canada

Federal partner organizations

Note: Other government departments (e.g., the Department of Justice, Indigenous Services Canada, etc.) are supporting the Canadian Drugs and Substances Strategy (CDSS). However, they are not captured in this Horizontal Initiative table, as they did not receive targeted funding to support the "Renewed Canadian Drugs and Substances Strategy".

Start Date of the Horizontal initiative

April 1, 2017 (first reporting cycle from 2017-18 to 2022-23)

End Date of the Horizontal initiative

March 31, 2028

Description of the Horizontal initiative

The Canadian Drugs and Substances StrategyFootnote 1 is the federal government's comprehensive response to substance-related harms, including the overdose crisis. The CDSS is an all-substances strategy, centered on promoting public health and protecting public safety. The strategy covers a broad range of legal and illegal substances, such as tobacco, cannabisFootnote 2, alcohol, and opioids. The goal of the CDSS is to improve the health and safety of all Canadians by minimizing the impact of substance use related harms for individuals, families, and communities. It is based on four interconnected foundational elements: prevention and education, substance use services and supports, evidence, and substance controls, such as law enforcement and regulation.

Following the Budget 2023 announcement, the CDSS was renewed and received $358.6M over 5 years (2023-24 to 2027-28) and $5.7M ongoing to Health Canada (HC), Public Health Agency of Canada (PHAC), Public Safety (PS), the Royal Canadian Mounted Police (RCMP), and Public Services and Procurement Canada (PSPC) and Global Affairs CanadaFootnote 3 (GAC). The renewed CDSS will focus on a full continuum of evidence-based health services and supports, from prevention to harm reduction to treatment and recovery. In addition, the renewed CDSS will continue to support efforts to address illegal production and trafficking, with a focus on organized crime, and surveillance and research activities to build the evidence base to support innovative solutions to address substance-related harms and deaths, including the overdose crisis.

The renewed CDSS has introduced the principle of equity, alongside the principles of compassion, collaboration, and comprehensiveness to help guide federal actions to address the overdose crisis and the complex factors that contribute to substance-related harms, including links with mental health, housing, economic insecurity, and chronic pain, among others.

Governance structures

The Minister of Mental Health and Addictions and the Associate Minister of Health leads and coordinates the CDSS, supported by HC in collaboration with over 15 federal departments and agencies. The Strategy is coordinated through a Deputy Minister (DM) level Task Force supported by an Assistant Deputy Minister (ADM) level working group which provides senior-level oversight and strategic direction to the Director-General (DG) level Steering Committee.

These Committees reflect and support the CDSS' comprehensive approach to substance use issues and are composed of federal departments/agencies whose mandates are relevant to the four interconnected foundational elements: prevention and education; substance use services and supports; evidence; and substance controls (including departments that formally received CDSS funding and those that do not). The Committees meet at least twice a year, or ad hoc, as required. Secretariat support for the CDSS is provided by HC. Federal/provincial/territorial (F/P/T) engagement is achieved through existing mechanisms, including the F/P/T Committee on Substance Use (CSU), currently co-chaired by HC and the Province of British Columbia (moving forward Manitoba will be the co-chair of CSU starting in 2024-25).

Total federal funding allocated from 2017-18 to 2027-28 (dollars)

$1,131,640,121 (includes $772,980,012 for first reporting cycle from 2017-18 to 2022-23)

Total federal funding planned spending to March 31, 2024 (dollars)

$822,254,941 (includes $780,889,619 for first reporting cycle from 2017-18 to 2022-23)

Total federal actual spending to March 31, 2024 (dollars)

$995,752,452 (includes $957,272,908 first reporting cycle from 2017-18 to 2022-23)

Date of last renewal of the Horizontal initiative

September 2023

Total federal funding allocated at the last renewal and source of funding (dollars)

$358,660,109. Budget 2023.

Additional federal funding received after last renewal (dollars)

Not applicable.

Total planned spending since last renewal to March 31, 2024

$41,365,322 (second reporting cycle from 2023-24 to 2027-28)

Total actual spending since last renewal to March 31, 2024

$38,479,544 (second reporting cycle from 2023-24 to 2027-28)

Fiscal year of planned completion of next evaluation

2028-2029

Performance highlights

The overdose crisis is one of the most serious public health threats in Canada's recent history with devastating impacts on individuals, friends and families, and communities across the country. Canada continued to experience an unrelenting rate of overdose deaths and substance-use related harms, largely due to the dangerous synthetic illegal drug supply that is unpredictable and increasingly toxic. From January to December 2023, apparent opioid toxicity claimed the lives of at least 8,049 Canadians. This is an average of 22 deaths per day, bringing Canada to a total of at least 44,592 apparent opioid-toxicity deaths between January 2016 and December 2023. People who use drugs are experiencing higher risks related to an increasingly unpredictable and dangerous synthetic illegal drug supply, which is intensifying due to the presence of fentanyl and other substances. Fentanyl and its analogues comprise the largest share of opioids submitted for analysis by law enforcement. Of all accidental apparent opioid toxicity deaths between January and December 2023, 82% involved fentanyl (which appears to have stabilized in recent years) and 88% involved only opioids that were non-pharmaceutical (9% higher than the same period in 2023). More than half (61%) of accidental apparent opioid toxicity deaths in 2023 (January to December) also involved a stimulant, reflecting the polysubstance nature of this crisis. Of the accidental apparent stimulant toxicity deaths in 2023 (January to December), 64% involved cocaine, while 55% involved methamphetamines. Contaminants such as benzodiazepines and xylazine, are also in the dangerous synthetic illegal drug supply.

In 2023-24, The Office of Audit and Evaluation published the Horizontal Evaluation of the Canadian Drugs and Substance Strategy. The department, with federal partners, made significant progress to address the evaluation's recommendations. In October 2023, the Canadian Drugs and Substances Strategy: The Government of Canada's approach to substance use related harms and the overdose crisis and the Canadian Drugs and Substances Strategy's data and evidence framework were published. The evaluation recommended addressing evidence gaps to get a better understanding of the impact of services and supports. To monitor the differential impacts of harm reduction services a new dynamic, user-friendly dashboard with enhanced supervised consumption site data was developed and published in November 2023. CDSS governance has been refreshed to incorporate CDSS partners' feedback and reflect linkages with DM and ADM federal tables to clarify roles and responsibilities and streamline ongoing information sharing, as recommended in the evaluation. HC, in consultation with CDSS funded partners, developed new outcomes and indicators that are better aligned with the renewed CDSS, new initiatives and areas of focus, as reflected in this report.

In 2023-24, HC, worked with federal partners to renew the CDSS framework for federal actions across four interconnected foundational elements: prevention; substance use services and supports including timely and accessible harm reduction, treatment and recovery services; vital data collection; as well as substance control efforts to stem the flow of dangerous synthetic illegal drugs into our communities.

Specific key activities across the four integrated action areas related to substance use are outlined below:

Prevention and education

The renewed CDSS continued to support public education efforts to raise awareness of substance-related harms, promote help-seeking and reduce stigma, and community-led efforts to prevent, delay and reduce substance use and related harms among youth. Examples of activities that were undertaken in 2023 and 2024 include:

In addition, the PHAC launched a new Grants and Contributions program that will support participating communities/organizations in developing a tailored approach to substance use prevention, based on local data and analysis of the community's identified needs and risk factors for youth substance use. The new Youth Substance Use Prevention Program (YSUPP) is based on the Icelandic Prevention Model (IPM) and supports community-led efforts to prevent, delay and reduce substance use among youth. In February 2024, the program established a Knowledge Development and Exchange Hub that will be responsible for leading a pan-Canadian youth substance use prevention community of practice, and facilitating the sharing of information, knowledge and best practices among YSUPP funded projects. The YSUPP Call for Proposals closed on January 15, 2024. In March 2024, the PHAC issued seven grants to successful applicants through the first YSUPP Call for Proposals. Funded communities include two in British Columbia, one in Saskatchewan, one in Nova Scotia and three in Ontario.

Substance use services and supports

The renewed CDSS continued to support a full continuum of integrated, evidence-based, as well as innovative substance use services and supports to meet the diverse needs of people who use substances. This includes support for pilot projects, through HC's Substance Use and Addictions Program (SUAP) which provides funding for substance use prevention, harm reduction and treatment initiatives across the country at the community, regional and national level. SUAP's 2023 Call for Proposals closed on November 22, 2023, and included four funding priorities:

In response to the Call for Proposals, launched in September 2023, SUAP received nearly 700 proposals with a total ask of over $2 billion. HC is currently in the process of setting up contribution agreements with success.

Harm reduction measures such as supervised consumption sites and administration of naloxone are a component of the Government of Canada's comprehensive public health strategy. Health Canada continued to administer the legislative framework for supervised consumption services that provide a safe, clean space for people to bring their own drugs to use, in the presence of trained staff. This prevents accidental overdoses and reduces the spread of infectious diseases, such as HIV. Supervised consumption sites may offer a range of evidence-based harm reduction services, such as drug checking. The sites also provide access to important health and social services, including substance use treatment for those who are ready, and can reduce public drug use. From April 2023 - March 2024 there were 9,867 overdoses at supervised consumption sites, 4,077 overdoses required the use of naloxone, and none were fatal. From January 2017 to May 2024, there were 515,719 total referrals to health and social services.

Additionally, in 2023-24, HC developed a legislative proposal to be included in the Budget Implementation Act, 2024, which would amend the Controlled Drugs and Substances Act (CDSA) to include new regulation-making authorities. These new authorities could be used to develop a new regulatory framework to authorize supervised consumption and drug checking services. Such a regulatory framework could provide more stability and transparency for service providers by establishing clear and predictable regulatory requirements, while maintaining strict controls that are consistent with the public health and public safety objectives of the Act.

Evidence

Under the renewed CDSS, HC and partners continued to support accurate, timely, and reliable data and research, essential to policy development and decision making, in the following ways:

On November 9, 2023, HC hosted the first CDSS Data and Evidence Partners Table (DEPT) Results Day. This annual event is an opportunity for partners to share new monitoring, surveillance and research, and/or other relevant information with each other to promote collaboration and sharing of information with a goal of addressing identified data and evidence gaps. The next Results Day is planned for October 2024.

To support monitoring, reporting, and policy and program development on the overdose crisis, PHAC has highly skilled Public Health Officers in jurisdictions across Canada to enable critical surveillance and data collection relating to overdose mortality, morbidity, and emergency medical services. Quarterly data releases inform federal and provincial/territorial responses to the overdose crisis. For the 2023-24 fiscal year, nine Public Health Officers were deployed across nine jurisdictions.

Substance controls

The renewed CDSS guides federal efforts to control substances and precursor chemicals to ensure that they are available for legitimate purposes, such as clinical trials or medical uses, while also giving law enforcement and border control authorities the tools that they need to enforce the laws that keep people living in Canada safe and address the harms of the illegal drug trade. The renewed CDSS also supports law and border enforcement partners across the country to address the role of organized crime in the production, diversion and trafficking of toxic illegal drugs by supporting major drug enforcement operations both domestically and internationally and the dismantling of illegal drug labs.

HC continued to regulate access to controlled substances and precursor chemicals under the CDSA and its regulations to mitigate their public health and public safety risks, including minimizing the risk that they will be diverted to the illegal market, while supporting access to them for legitimate purposes. This is done by administering the CDSA and its regulations and through related compliance and enforcement activities. The RCMP and PSPC continued working with law enforcement partners to address illegal drug production and trafficking, disrupt their global flow, and keep communities safe. The Forensic Accounting Management Group (FAMG) of PSPC continued providing dedicated forensic accounting services that target complex and sophisticated organised drug crime investigations.

Canada also worked closely with key international partners, like the United States, to coordinate a global approach to address the public health and public safety risks of synthetic drugs though the Opioids Action Plan (OAP), the North American Drug Dialogue (NADD), the Trilateral Fentanyl Committee (TFC), in the hemisphere through the Inter-American Drug Abuse Control Commission (known by its Spanish acronym "CICAD") and globally through the Commission on Narcotic Drugs (CND), and the Global Coalition to Address Synthetic Drug Threats.

Participating federal departments and agencies have identified the following key specific substance control activities in 2023-24 under the renewed CDSS:

Health Canada (HC)

Public Safety (PS)

Royal Canadian Mounted Police (RCMP)

Global Affairs Canada (GAC)

GAC is committed to collaborating, sharing, and advancing accurate information about Canada's drug legislation and policies and delivering capacity building programming to address the production and flow of illegal drugs and substances to and through Canada from source destinations.

HC continued to work with federal partners on progress towards the shared CDSS goal to reduce overall rates of substance use related harms and overdose deaths in Canada. This report describes the impacts of actions taken through the CDSS in 2023-24.

Contact Information

Health Canada

Aysha Mawani
Director General
Controlled Substances and Opioid Response Directorate
Controlled Substances and Cannabis Branch
aysha.mawani@hc-sc.gc.ca
613-863-3160

Horizontal initiative framework

Horizontal initiative: Renewed Canadian Drugs and Substances Strategy

Shared outcome: Reduction in overall rates of substance-related harms among people living in Canada

Horizontal initiative framework: Departmental funding by theme (dollars)
Name of theme Theme Area A:
Targeted actions to address overdose crisis
Theme Area B:
Investing in community actions to address the overdose crisis and substance-related harms
Theme Area C:
Building evidence-based capacity to support equitable policy and programming decisions
Theme Area D:
Enforcement activities to support a public health approach to substance use
Internal Services
Theme outcomes

People living in Canada have modified behaviours to reduce substance-related harms

Legislation, regulations, and government activities support legitimate uses of the controlled substances and precursor chemicals while disrupting illegal activities

People living in Canada have modified behaviours to reduce substance-related harms Population-specific research, data and intelligence on substance-related harms and the illegal drug market are available to support evidence-based decision-making Legislation, regulations, and government activities support legitimate uses of the controlled substances and precursor chemicals while disrupting illegal activities N/A
Health Canada $68,732,682 $144,000,000 $16,857,223 $27,739,093 $12,727,914
Public Health Agency of Canada N/A $19,123,115 $14,403,661 N/A $2,670,224
Public Safety N/A N/A N/A $4,470,292 $124,546
Royal Canadian Mounted Police N/A N/A N/A $39,062,958 $2,923,023
Public Services and Procurement Canada N/A N/A N/A $5,271,705 $553,673
Global Affairs Canada N/A N/A N/A $0 $0
Total $68,732,682 $163,123,115 $31,260,884 $76,544,048 $18,999,380

Note: Departmental funding for each theme identifies the total departmental top-up funding (in dollars) allocated from 2023-24 to 2027-28 for that theme and equals the total of the departmental activity-level funding for that theme, as identified in the following theme horizontal initiative (HI) activities financial tables below.

Performance information

Horizontal initiative overview
Name of horizontal initiative Total federal funding allocated from 2023–24 to 2027–28 (dollars)footnote a 2023–24 Federal funding allocated (dollars)Footnote b 2023–24 Actual spending (dollars)footnote c Horizontal initiative shared outcome Performance indicator(s) Target(s) Date to achieve target 2023–24 Actual results

Renewed Canadian Drugs and Substances Strategy

358,660,109

41,365,322

38,479,544

SO 1.0 Reduction in overall rates of substance-related harms among people living in Canada

1.1.1.1 Rate of deaths attributable to substance use per 100,000 population

10.0 apparent opioid toxicity deaths per 100,000 population

6.0 apparent stimulant toxicity deaths per 100,000 populationFootnote d

March 31, 2028

Opioids: 20.8 deaths per 100 000

Stimulants: 14.0 deaths per 100,000

1.1.1.2 Rate of hospitalizations attributed to substance use per 100,00 populationFootnote e

16.0 apparent opioid-related hospitalizations per 100,00

7.0 apparent stimulant-related poisoning hospitalizations per 100,000Footnote f

March 31, 2028

Opioids: 20.2 opioids-related poisoning hospitalizations per 100,000

Stimulants: 7.7 stimulant-related poisoning hospitalizations per 100,000 population

Footnote a

Funding includes $18,999,380 for Internal Services.

Return to Footnote a referrer

Footnote b

Funding includes $2,764,985 for Internal Services.

Return to Footnote b referrer

Footnote c

Funding includes $2,764,983 for Internal Services.

Return to Footnote c referrer

Footnote d

Target is based on rate of pre-pandemic levels in 2019 which sets a starting point of 9.9 deaths per 100,000 population for opioids and 6.0 deaths per 100,000 population for stimulants.

Return to Footnote d referrer

Footnote e

Hospital stays for harm caused by all substances except cannabis (for example, opioids, stimulants, alcohol and other substances).

Return to Footnote e referrer

Footnote f

Target is based on rate of pre-pandemic levels in 2019 which sets a starting point of 15.5 opioids-related poisoning hospitalizations per 100,000 population and 7.5 stimulant-related poisoning hospitalizations per 100,000 population.

Return to Footnote f referrer

Theme horizontal initiative activities

Theme A – Details
Name of theme Total federal theme funding allocated from 2023–24 to 2027–28 (dollars) 2023–24 Federal theme allocated funding (dollars) 2023–24 Federal theme actual spending (dollars) Theme outcome(s) Theme performance indicator(s) Theme target(s) Date to achieve theme target 2023–24 Actual results

Targeted actions to address overdose crisis

68,732,682

14,710,921

10,235,644

2.1 People living in Canada have modified their behaviours to reduce substance-related harms

2.1.1.1 Percentage of Canadians who consumed at least two substances at the same time in the 12 months prior to reporting

To be established in October 2024footnote a

March 31, 2026

N/A

2.1.1.2 Percent of youth (Grade 7-12) living in Canada who used opioidsFootnote b or stimulantsfootnote c in the last 12 months and/or alcohol in the last 30 days

Opioids: 2.5%

Stimulants: under 3%

Alcohol: under 19%Footnote d

March 31, 2028

N/AFootnote e

2.2 Legislation, regulations, and government activities support legitimate uses of the controlled substances and precursor chemicals while disrupting illegal activities

2.2.1.1 Percent of authorizations processed for controlled substances and precursor chemicals within service standards by type of authorization

80%

March 31, 2025, and annually

AR 2.2.1.1

Footnote a

Canadian Alcohol and Drugs Survey (CADS) data to establish a starting point and target for this indicator is expected to be available in October 2024.

Return to Footnote a referrer

Footnote b

Opioids include at least one of the following: heroin and pharmaceutical opioid-based pain relievers used to "get high"; oxycodone; fentanyl; or other prescribed pain relievers (codeine, morphine, Tylenol 3® etc.).

Return to Footnote b referrer

Footnote c

Stimulants include at least one of the following: amphetamines; cocaine; BZP/TFMPP; Bath Salts; and pharmaceutical stimulants used to "get high": including medicine to treat ADHD (Ritalin®, Concerta®, Adderall®, Dexedrine®) and other stimulants (uppers and bennies).

Return to Footnote c referrer

Footnote d

Target is based on 2021-22 CSTADS (representative of grade 7 to 12 (Secondaire I to V in Quebec) in Canada) results which sets a starting point of: Opioids: 3.5%; Stimulants: 6.0%; and Alcohol: 24.6%.

Return to Footnote d referrer

Footnote e

Results for the 2023-24 CSTADS cycle will be available March 31, 2025.

Return to Footnote e referrer

Theme A – Horizontal initiative activities
Departments Link to department's Program Inventory Horizontal initiative activity Total federal funding allocated to each horizontal initiative activity from 2023–24 to 2027–28 (dollars) 2023–24 Federal funding allocated for each horizontal initiative activity (dollars) 2023–24 Actual spending for each horizontal initiative activity (dollars) 2023–24 Horizontal initiative activity expected result(s) 2023–24 Horizontal initiative activity performance indicator(s) 2023–24 Horizontal initiative activity target(s) Date to achieve horizontal initiative activity target 2023–24 Actual results
HC Controlled Substances A.1 Implementation Support for the Canadian Drugs and Substances Strategy 55,583,552 12,030,398 8,429,278 ER 3.1 PI 3.1.1.1 T 3.1.1.1 March 31, 2028 AR 3.1.1.1
PI 3.1.1.2 T 3.1.1.2 March 31, 2026 AR 3.1.1.2
A.2 Streamlining authorizations for supervised consumption sites and drug checking services 7,254,212 1,501,539 1,016,992 ER 3.2 PI 3.2.1.3 T 3.2.1.3 March 31, 2026 AR 3.2.1.3
PI 3.2.1.4 T 3.2.1.4 March 31, 2026 AR 3.2.1.4
A.3 Build up evidence for substance use services and supports and evaluating innovative approaches 5,894,918 1,178,984 789,374 PI 3.2.1.1 T 3.2.1.1 March 31, 2026 AR 3.2.1.1
Theme B – Details
Name of theme Total federal theme funding allocated from 2023–24 to 2027–28 (dollars) 2023–24 Federal theme allocated funding (dollars) 2023–24 Federal theme actual spending (dollars) Theme outcome(s) Theme performance indicator(s) Theme target(s) Date to achieve theme target 2023–24 Actual results

Investing in community actions to address the overdose crisis and substance-related harms

163,123,115

7,612,586

7,837,185

2.1 People living in Canada have modified behaviours to reduce substance-related harms

2.1.1.1 Percentage of Canadians who consumed at least two substances at the same time in the 12 months prior to reporting

To be established in October 2024footnote a

March 31, 2026

Not available

2.1.1.2 Percent of youth (Grade 7-12) living in Canada who used opioidsFootnote b or stimulantsfootnote c in the last 12 months, and/or alcohol in the last 30 days

Opioids: 2.5%

Stimulants: under 3%

Alcohol: under 19%Footnote d

March 31, 2028

Not availableFootnote e

Footnote a

Canadian Alcohol and Drugs Survey (CADS) data to establish a starting point and target for this indicator is expected to be available in October 2024.

Return to Footnote a referrer

Footnote b

Opioids include at least one of the following: heroin and pharmaceutical opioid-based pain relievers used to "get high": oxycodone, fentanyl, or other prescribed pain relievers (codeine, morphine, Tylenol 3® etc.).

Return to Footnote b referrer

Footnote c

Stimulants include at least one of the following: amphetamines; cocaine; BZP/TFMPP; Bath Salts; and pharmaceutical stimulants used to "get high": including medicine to treat ADHD (Ritalin®, Concerta®, Adderall®, Dexedrine®) and other stimulants (uppers and bennies).

Return to Footnote c referrer

Footnote d

Target is based on 2021-22 Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS) (representative of grade 7 to 12 (Secondaire I to V in Quebec) in Canada) results which sets a starting point of: Opioids: 3.5%; Stimulants: 6.0%; and Alcohol: 24.6%.

Return to Footnote d referrer

Footnote e

Results for the 2023-24 CSTADS cycle will be available March 31, 2025.

Return to Footnote e referrer

Theme B – Horizontal initiative activities
Departments Link to department's Program Inventory Horizontal initiative activity Total federal funding allocated to each horizontal initiative activity from 2023–24 to 2027–28 (dollars) 2023–24 Federal funding allocated for each horizontal initiative activity (dollars) 2023–24 Actual spending for each horizontal initiative activity (dollars) 2023–24 Horizontal initiative activity expected result(s) 2023–24 Horizontal initiative activity performance indicator(s) 2023–24 Horizontal initiative activity target(s) Date to achieve horizontal initiative activity target 2023–24 Actual results
HC Controlled Substances B.1 Substance Use and Addictions Program 144,000,000 6,000,000 5,900,469 ER 3.2 PI 3.2.1.2 T 3.2.1.2 March 31, 2025 AR 3.2.1.2
PHAC Health Promotion B.2 Youth Substance Use Prevention Program 19,123,115 1,612,586 1,936,716 ER 3.1 PI 3.1.2.1 T 3.1.2.1 March 31, 2028 AR 3.1.2.1
Theme C – Details
Name of theme Total federal theme funding allocated from 2023–24 to 2027–28 (dollars) 2023–24 Federal theme allocated funding (dollars) 2023–24 Federal theme actual spending (dollars) Theme outcome(s) Theme performance indicator(s) Theme target(s) Date to achieve theme target 2023–24 Actual results
Building evidence-based capacity to support equitable policy and programming decisions 31,260,884 8,227,646 9,896,247 3.3 Population-specific research, data and intelligence on substance-related harms and the illegal drug market are available to support evidence-based decision-making 3.3.1.2 Percent of data requests received by the Drug Analysis Service answered within 5 working days or negotiated date. 100% March 31, 2025 100%
3.3.2.1 Proportion of jurisdictions with Public Health Officers in place that are reporting data in time for scheduled quarterly releases. 100% March 31, 2025 100%
Theme C – Horizontal initiative activities
Departments Link to department's Program Inventory Horizontal initiative activity Total federal funding allocated to each horizontal initiative activity from 2023–24 to 2027–28 (dollars) 2023–24 Federal funding allocated for each horizontal initiative activity (dollars) 2023–24 Actual spending for each horizontal initiative activity (dollars) 2023–24 Horizontal initiative activity expected result(s) 2023–24 Horizontal initiative activity performance indicator(s) 2023–24 Horizontal initiative activity target(s) Date to achieve horizontal initiative activity target 2023–24 Actual results
HC Controlled Substances C.1 Implementation of CDSS Data and Evidence Framework 13,805,961 4,729,343 6,529,075 ER 3.3 PI 3.3.1.1 T 3.3.1.1 March 31, 2025 AR 3.3.1.1
PI 3.3.1.3 T 3.3.1.3 March 31, 2025 AR 3.3.1.3
3,051,262 623,721 712,245 PI 3.3.1.4 T 3.3.1.4 March 31, 2025 AR 3.3.1.4
PI 3.3.1.5 T 3.3.1.5 March 31, 2025 AR 3.3.1.5
PHAC Evidence for Health Promotion, and Chronic Disease and Injury Prevention C.2 PHAC Stabilizing Public Health Surveillance 14,403,661 2,874,582 2,654,927 PI 3.3.2.1 T 3.3.2.1 March 31, 2025 AR 3.3.2.1
Theme D – Details
Name of theme Total federal theme funding allocated from 2023–24 to 2027–28 (dollars) 2023–24 Federal theme allocated funding (dollars) 2023–24 Federal theme actual spending (dollars) Theme outcome(s) Theme performance indicator(s) Theme target(s) Date to achieve theme target 2023–24 Actual results

Enforcement activities to support a public health approach to substance use

76,544,048

8,049,184

7,745,485

2.2 Legislation, regulations, and government activities support legitimate uses of the controlled substances and precursor chemicals while disrupting illegal activities.

2.2.1.2 Percentage of licensed dealers inspected that are deemed to be compliant with the Controlled Drugs and Substances Act (CDSA) and its regulations

80%footnote a

March 31, 2025

88%

2.2.4.1 Increase in the of number of drug-related charges laid by the RCMP and percentage of charges laid by Federal Policing (breakdown of charges by type: possession, trafficking, import/export, production) (FP)Footnote b

5% increase over the length of the CDSS.

Baseline of drug-related charges laid by RCMP in FY 2022-23 is 6,555

March 31, 2028

6,681footnote c

2.2.4.2 Increase in the number of illegal substance interdictions supported by the National Drug Coordination Team for domestic and international enforcement operations including a focus on clandestine laboratories, synthetic drugs, including opioids, new psychoactive substances and novel substances, which when, mixed increase the toxicity (FP)

TBD to be established by March 31, 2025

March 31, 2028

N/AFootnote d

Footnote a

Health Canada will continue to target Licensed Dealers with a higher risk of product diversion using a risk-based approach to protect the health and safety of Canadians. This risk-based, targeted inspection approach may lead to a lower percentage of industry compliance than the planned result. Using historical data available at this time, the target of 80% is thought to be realistic.

Return to Footnote a referrer

Footnote b

As part of its programming in support of CDSS, the RCMP expects to see an increase in serious drug-related charges, including drug trafficking, import/export and production. In order to present a full picture of drug-related charges, this RCMP indicator (2.2.4.1) will provide a breakdown of drug-related charges. Possession charges may fall into three categories: 'Possession' (which may include personal use), 'Possession for the purpose of trafficking', and 'Possession for the purpose of distributing'. However, due to reporting limitations, the possession charges reported under 2.2.4.1 will represent the aggregate total of charges related to "Possession for the purpose of trafficking" and "Possession for the purpose of distributing" and charges for simple drug possession offences will not be added to this performance metric.

Return to Footnote b referrer

Footnote c

Between FY 2022-23 and FY 2023-24, there was a 1.9% increase in the number of drug-related charges laid by the RCMP. A total of 6,681 drug-related charges were laid by the RCMP, with 27% (1,794) laid by Federal Policing. Of the 27% (1,794) charges laid by Federal Policing: 80.5% (1,444) were related to trafficking offences, 7.7% (138) were related to possession offences, 105 (5.9%) were cannabis-related, 102 (5.7%) were related to import/export offences, 5 (0.3%) were related to Production offences.

Return to Footnote c referrer

Footnote d

Funding for the renewed CDSS came into effect on April 1, 2024, for a select number of positions attributed to the RCMP. The RCMP is presently working through various staffing processes to fill the positions, and commence the work to address the recommendations and planned actions outlined in the Horizontal Initiative.

Return to Footnote d referrer

Theme D – Horizontal initiative activities
Departments Link to department's Program Inventory Horizontal initiative activity Total federal funding allocated to each horizontal initiative activity from 2023–24 to 2027–28 (dollars) 2023–24 Federal funding allocated for each horizontal initiative activity (dollars) 2023–24 Actual spending for each horizontal initiative activity (dollars) 2023–24 Horizontal initiative activity expected result(s) 2023–24 Horizontal initiative activity performance indicator(s) 2023–24 Horizontal initiative activity target(s) Date to achieve horizontal initiative activity target 2023–24 Actual results
PS Crime Prevention D.1 Support to Law Enforcement 4,470,292 0 0 ER 3.3 PI 3.3.3.1 T 3.3.3.1 March 31, 2028 AR 3.3.3.1
RCMP Criminal Intelligence Service Canada (CISC) D.2 Support to Law Enforcement 6,772,550 1,057,686 1,057,686 PI 3.3.4.1 T 3.3.4.1 March 31, 2025 AR 3.3.4.1
Federal Policing Intelligence (FP) 11,454,941 656,173 656,173 PI 3.3.4.2 T 3.3.4.2 March 31, 2025 AR 3.3.4.2
Federal Policing Investigations 13,182,652 360,664 360,664 PI 3.3.4.3 T 3.3.4.3 N/A AR 3.3.4.3
Federal Policing International Operations 7,652,815 0 0 ER 2.2 PI 2.2.4.3 T 2.2.4.3 March 31, 2028 AR 2.2.4.3
HC Controlled Substances D.3 Support to Law Enforcement 27,739,093 5,502,410 5,198,711 ER 3.4 PI 3.4.1.1 T 3.4.1.1 March 31, 2025 AR 3.4.1.1
PI 3.4.1.2 T 3.4.1.2 March 31, 2025 AR 3.4.1.2
PSPC Increased forensic accounting services for drug related criminal investigation D.4 Support to Law Enforcement 5,271,705 472,251 472,251 PI 3.4.5.1 T 3.4.5.1 N/A AR 3.4.5.1
PI 3.4.5.2 T 3.4.5.2 N/A AR 3.4.5.2
PI 3.4.5.3. T 3.4.5.3 N/A AR 3.4.5.3
GAC Diplomacy, Advocacy and International Agreements Support to Law Enforcementfootnote a 0 0 0 PI 3.4.6.1 T 3.4.6.1 March 31, 2025 AR 3.4.6.1
PI 3.4.6.2 T 3.4.6.2 March 31, 2025 AR 3.4.6.2
Footnote a

HI activity funded through ongoing funding. No new funding was sought for these activities under the 2023-24 TB Submission. GAC is an unfunded partner within the Renewed CDSS Horizontal Initiative framework. GAC continues to support international enforcement efforts to stem the production and flow of toxic illegal drugs into Canadian and key partner countries.

Return to Footnote a referrer

Total spending, all themes
ThemeFootnote * Total federal funding allocated from 2023–24 to 2027–28 (dollars) 2023–24 Federal theme allocated funding (dollars) 2023–24 Federal theme actual spending (dollars)
Theme A 68,732,682 14,710,921 10,235,644
Theme B 163,123,115 7,612,586 7,837,185
Theme C 31,260,884 8,227,646 9,896,247
Theme D 76,544,048 8,049,184 7,745,485
Total, all themes 339,660,729 38,600,337 35,714,561
Footnote *

Theme amounts exclude Internal Services

Return to Footnote * referrer

Variance Explanations

Health Canada

The variances between planned and actual expenditures for Theme A and Theme C are mainly due to the late receipt of in-year funding and its impact on procurement timelines, resulting in significant contract delays and in-year planned staffing.

Public Health Agency of Canada

The variance between planned and actual expenditures for Theme B is mainly due to an internal reallocation to support additional projects that were planned.

Expected results

  1. ER 1 – Long term expected results
    • 1.1 Reduction in overall rates of substance-related harms among people living in Canada
  2. ER 2 – Medium term expected results
    • 2.1 People living in Canada have modified behaviours to reduce substance-related harms
    • 2.2 Legislation, regulations, and government activities support legitimate uses of the controlled substances and precursor chemicals while disrupting illegal activities
  3. ER Short term expected results
    • 3.1 People and communities in Canada have increased capacity, knowledge, skills, and resources regarding substance use and related harms
    • 3.2 Improved equitable access to services and supports to reduce substance-related harms
    • 3.3 Population-specific research, data and intelligence on substance-related harms and the illegal drug market are available to support evidence-based decision-making
    • 3.4 Enhanced supports for enforcement and regulatory activities related to controlled substances and precursor chemicals

Performance indicators

  1. PI 1 – Long term indicators
    • 1.1.1.1 Rate of deaths attributable to substance use per 100 000 population
    • 1.1.1.2 Rate of hospitalizations attributed to substance use per 100,000 populationFootnote 4
  2. PI 2 – Medium term indicators
    • 2.1.1.1 Percentage of Canadians who consumed at least two substances at the same time in the 12 months prior to reporting
    • 2.1.1.2 Percent of youth living in Canada who used opioidsFootnote 5 or stimulantsFootnote 6 in the last 12 months, and/or alcohol in the last 30 days)
    • 2.2.1.1 Percentage of authorizations processed for controlled substances and precursor chemicals within service standards by type of authorization
    • 2.2.1.2 Percentage of licensed dealers inspected that are deemed to be compliant with the CDSA and its regulations
    • 2.2.4.1 Increase in the number of drug-related charges laid by the RCMP and percentage of charges laid by Federal Policing (FP) (breakdown of charges by type: possession, trafficking, import/export, production)Footnote 7
    • 2.2.4.2 Increase in the number of significant illegal substance interdictions supported by the National Drug Coordination Team for domestic and international enforcement operations including a focus on clandestine laboratories, synthetic drugs, including opioids, new psychoactive substances and novel substances which when mixed increase the toxicity (FP)
    • 2.2.4.3 Increase in the volume of illegal drugs with a nexus to Canada disrupted in coordination with the RCMP's International Network of Liaison Officers and Analysts Deployed Overseas
  3. PI 3 Short term indicators
    • 3.1.1.1 Percentage of people living in Canada who have stigmatizing views towards and about people who use substances
    • 3.1.1.2 Percent of people living in Canada aware of the risks associated with substance use
    • 3.1.2.1 Percent of program participants reporting increase in knowledge and/or skills related to prevention of substance use harms
    • 3.2.1.1 Percent of Canadians who had support navigating substance use services
    • 3.2.1.2 Percent change in the number of clients accessing services funded by SUAP that aim to reduce substance use harms
    • 3.2.1.3 Average number of visits to supervised consumption sites (SCS) per year
    • 3.2.1.4 Average number of drug checks at applicable SCS
    • 3.3.1.1 Number drug notifications issued on newly identified potent illegal drugs
    • 3.3.1.2 Percent of data requests received by the Drug Analysis Service answered within 5 working days or negotiated date
    • 3.3.1.3 Percentage of Drug Analysis Services' law enforcement and public health partners who report receiving useful data and intelligence on the illegal drug market
    • 3.3.1.4 Percent of surveys that can report on equity variables beyond age and sex/gender
    • 3.3.1.5 Percent of planned evidence products completed within planned timeframe per fiscal year
    • 3.3.2.1 Proportion of jurisdictions with Public Health Officers in place that are reporting data in time for scheduled quarterly releases
    • 3.3.3.1 Percentage of law enforcement partner recipients who deem overdose mapping application knowledge products (e.g. reports, infographics) on the illegal drug market to be useful
    • 3.3.4.1 Number of briefings that support law enforcement and/or disruption actions (CISC)
    • 3.3.4.2 Number of illegal-drug related intelligence products / initiatives shared internally and/or externally with partners (FP)
    • 3.3.4.3 Number and percentage of drug-related Serious and Organized Crime occurrences with a transnational nexus (FP)
    • 3.4.1.1 Number of seized exhibits received from law enforcement agencies for laboratory analysis
    • 3.4.1.2 Percent of pharmacy stakeholders indicating an increased compliance awareness of regulatory requirements following compliance promotion
    • 3.4.5.1 Total number of Drug projects ongoing (open files)
    • 3.4.5.2 Number of reports released
    • 3.4.5.3 Total hours spent working on Drug investigations
    • 3.4.6.1 Number of illegal drug seizures in selected beneficiary countries made possible through GAC capacity-building funding
    • 3.4.6.2 Volume of illegal drugs seized in selected beneficiary countries made possible through GAC capacity-building funding

Targets

  1. T 1 – Long term targets
    • 1.1.1.1 Opioids:10.0 apparent opioid toxicity deaths per 100,000 population. Stimulants: 6.0 apparent stimulant toxicity deaths per 100,000 populationFootnote 8
    • 1.1.1.2 Opioids: 16.0 apparent opioid-related hospitalizations per 100,000; Stimulants: 7.0 apparent stimulant-related poisoning hospitalizations per 100,000Footnote 9
  2. T 2 – Medium term targets
    • 2.1.1.1 Target and starting point to be established in October 2024Footnote 10
    • 2.1.1.2 Opioids: 2.5%; Stimulants: under 3%; Alcohol: under 19%Footnote 11
    • 2.2.1.1 80%
    • 2.2.1.2 80%
    • 2.2.4.1 5% increase over the length of the CDSSFootnote 12
    • 2.2.4.2 TBD in the first year of the renewed CDSS. Starting point will be established by 03/2025
    • 2.2.4.3 TBD in the first year of the renewed CDSS. Starting point will be established by 03/2025
  3. T 3 – Short term targets
    • 3.1.1.1 Less than 20% of people living in Canada have stigmatizing viewsFootnote 13
    • 3.1.1.2 Targets to be established in 09/2024Footnote 14
    • 3.1.2.1 A Call for Proposals (CFP) was conducted in 2023-24. Targets will be updated following the awarding of funds by 03/2026Footnote 15
    • 3.2.1.1 41%Footnote 16
    • 3.2.1.2 10%
    • 3.2.1.3 19,000 visitsFootnote 17
    • 3.2.1.4 500 drug checksFootnote 18
    • 3.3.1.1 Demand DrivenFootnote 19
    • 3.3.1.2 100%Footnote 20
    • 3.3.1.3 80%Footnote 21
    • 3.3.1.4 25% of surveys can report on equity variables beyond age and sexFootnote 22
    • 3.3.1.5 80%Footnote 23
    • 3.3.2.1 100%
    • 3.3.3.1 75% of respondents deem the information useful; at least three knowledge products, based on at least one knowledge product per year, will be produced, commencing in FY 2025-26Footnote 24
    • 3.3.4.1 30Footnote 25
    • 3.3.4.2 20Footnote 26
    • 3.3.4.3 Demand driven
    • 3.4.1.1 Demand driven
    • 3.4.1.2 75%Footnote 27
    • 3.4.5.1 Demand driven based on number of cases and requests received by law enforcement partners
    • 3.4.5.2 Demand driven based on number of cases and requests received by law enforcement partners
    • 3.4.5.3 Demand driven based on number of cases and requests received by law enforcement partners
    • 3.4.6.1 Demand driven
    • 3.4.6.2 Demand driven

Actual results

  1. AR 1 – Long term Results
    • 1.1.1.1 Opioids: 20.8 deaths per 100,000 population Stimulants: 14.0 deaths per 100,000 population
    • 1.1.1.2 Opioids: 20.2 opioids-related poisoning hospitalizations per 100,000, Stimulants: 7.7 stimulant-related poisoning hospitalizations per 100,000 population
  2. AR 2 – Medium term Results
    • 2.1.1.1 Results will be available March 31, 2025
    • 2.1.1.2 Results for the 2023-24 cycle will be available March 31, 2025
    • 2.2.1.1 Results are as follows:
      Type of Authorization Controlled Substances Precursor Chemicals
      1. Issuance of New Licence/Registration 62% Class A: 94%
      Class B: 100%
      2. Licence renewals 99% 97%
      3. Issuance of Import/Export Permits 99% 97%
      4. Issuance of an Amendment to a Dealer's License 88% Class A: 96%
      5. Issuance of Test Kit Registration Number 95% Not applicable
    • 2.2.1.2 88%
    • 2.2.4.1 6,681 (1.9% increase)Footnote 28
    • 2.2.4.2 Not available Footnote 29
    • 2.2.4.3 Not availableFootnote 30
  3. AR – Short term Results
    • 3.1.1.1 24% of Canadians hold unsympathetic views towards people that use Opioids
    • 3.1.1.2 88% of respondents living in Canada were aware that polysubstance use increases the risk of developing serious health problems
    • 3.1.2.1 A Call for Proposals (CFP) was conducted in 2023-24. First year results will be updated following the awarding of funds by 03/2026
    • 3.2.1.1 44%
    • 3.2.1.2 Results to be available September 30, 2025
    • 3.2.1.3 13,984 visits per SCS
    • 3.2.1.4 405 (For calendar year 2023)
    • 3.3.1.1 69, compared to 71 in 2022-23
    • 3.3.1.2 100% (306/306), compared to 100% (302/302) in 2022-23
    • 3.3.1.3 Results to be available by 12/2024
    • 3.3.1.4 80% (4/5) have results available that include equity variables beyond sex/gender and age
    • 3.3.1.5 Results to be available by 10/2024
    • 3.3.2.1 100%
    • 3.3.3.1 First year results and starting point will be established in 2025-26 following selection of participant jurisdictions
    • 3.3.4.1 27Footnote 31
    • 3.3.4.2 5Footnote 32
    • 3.3.4.3 24% (160 occurrences)Footnote 33
    • 3.4.1.1 107,602
    • 3.4.1.2 94%Footnote 34
    • 3.4.5.1 60
    • 3.4.5.2 43
    • 3.4.5.3 13,700
    • 3.4.6.1 Nil
    • 3.4.6.2 Nil

Footnotes

Footnote 1

Canadian Drugs and Substances Strategy, https://www.canada.ca/en/health-canada/services/substance-use/canadian-drugs-substances-strategy.html

Return to footnote 1 referrer

Footnote 2

While cannabis is encompassed by the CDSS, federal activities, performance measures and funding amounts are reported on through a separate horizontal initiative (Renewal of the funding for the existing Federal Framework for the Legalization and Regulation of Cannabis in Canada).

Return to footnote 2 referrer

Footnote 3

Global Affairs Canada is also considered a federal partner organization but did not receive new funding through the renewal of the CDSS.

Return to footnote 3 referrer

Footnote 4

Hospital stays for harm caused by all substances except cannabis (for example, opioids, stimulants, alcohol and other substances).

Return to footnote 4 referrer

Footnote 5

Opioids include at least one of the following: heroin and pharmaceutical opioid-based pain relievers used to "get high"; oxycodone; fentanyl; or other prescribed pain relievers (codeine, morphine, Tylenol 3® etc.).

Return to footnote 5 referrer

Footnote 6

Stimulants include at least one of the following: amphetamines; cocaine; BZP/TFMPP; Bath Salts; and pharmaceutical stimulants used to "get high": including medicine to treat ADHD (Ritalin®, Concerta®, Adderall®, Dexedrine®) and other stimulants (uppers and bennies).

Return to footnote 6 referrer

Footnote 7

As part of its programming in support of CDSS, the RCMP expects to see an increase in serious drug-related charges, including drug trafficking, import/export and production. In order to present a full picture of drug-related charges, this RCMP indicator (2.2.2.1) will provide a breakdown of drug-related charges. Possession charges may fall into three categories: 'Possession' (which may include personal use), 'Possession for the purpose of trafficking', and 'Possession for the purpose of distributing'. However, due to reporting limitations, the possession charges reported under 2.2.2.1 will represent the aggregate total of charges related to "Possession for the purpose of trafficking" and "Possession for the purpose of distributing" and charges for simple drug possession offences will not be added to this performance metric.

Return to footnote 7 referrer

Footnote 8

Target is based on rate of pre-pandemic levels in 2019 which sets a starting point of 9.9 deaths per 100 000 population for opioids and 6.0 deaths per 100,000 population for stimulants.

Return to footnote 8 referrer

Footnote 9

Target is based on rate of pre-pandemic levels in 2019 which sets a starting point of 15.5 opioids-related poisoning hospitalizations per 100,000 population and 7.5 stimulant-related poisoning hospitalizations per 100,000 population.

Return to footnote 9 referrer

Footnote 10

CADS data to establish a starting point and target for this indicator is expected to be available in October 2024.

Return to footnote 10 referrer

Footnote 11

Target is based on 2021-22 Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS) (representative of grade 7 to 12 (Secondaire I to V in Quebec) in Canada) results which sets a starting point of: Opioids: 3.5%; Stimulants: 6.0%; and Alcohol: 24.6%.

Return to footnote 11 referrer

Footnote 12

Starting point: 6,555 drug-related charges laid by RCMP (2022-23).

Return to footnote 12 referrer

Footnote 13

Starting point: 26%, set in 2019.

Return to footnote 13 referrer

Footnote 14

Starting point: Alcohol: PAAHS (2023): 34% of people living in Canada are aware that consuming 1 to 2 standard drinks of alcohol per week increases the risk of colon cancer, breast cancer (28%), throat cancer (27%), mouth cancer (26%). Polysubstance: PCO POR on APH (2024): 88% of respondents living in Canada were aware that polysubstance use increases the risk of developing serious health problems (unpublished, will be published by September 30, 2024).

Return to footnote 14 referrer

Footnote 15

Starting point will be updated following the awarding of funds by 03/2026.

Return to footnote 15 referrer

Footnote 16

Starting point: 41% from 03/2022.

Return to footnote 16 referrer

Footnote 17

Starting point: 18,823 visits in 2020.

Return to footnote 17 referrer

Footnote 18

Starting point: 456 drug checks in 2022.

Return to footnote 18 referrer

Footnote 19

Starting point: 71, set in 2022-23.

Return to footnote 19 referrer

Footnote 20

Starting point to be established in 12/2024.

Return to footnote 20 referrer

Footnote 21

Starting point to be established in 12/2024.

Return to footnote 21 referrer

Footnote 22

Starting point to be established by 09/2024.

Return to footnote 22 referrer

Footnote 23

Starting point to be established by 09/2024.

Return to footnote 23 referrer

Footnote 24

Starting point to be established in 2025-26 following selection of participant jurisdictions.

Return to footnote 24 referrer

Footnote 25

Starting point: 30, set in 2021-22.

Return to footnote 25 referrer

Footnote 26

Starting point: 5, set in 2022-23.

Return to footnote 26 referrer

Footnote 27

Starting point is 96% following compliance promotion activities with industry stakeholders in 2022-23. Results were based on surveys received after the completion of compliance promotion activities, which had a relatively low response rate and were conducted over a partial fiscal year (therefore a full year of data is not available). Therefore, this very early baseline is not considered to be a reliable source to appropriately inform a target. The program will be integrating survey feedback as part of the compliance promotion sessions in an effort to receive a higher volume of survey responses to improve the reliability of feedback. The aim for the program is to raise awareness of regulatory requirements amongst at least 75% of the attendees participating in the compliance promotion sessions.

Return to footnote 27 referrer

Footnote 28

Between FY 2022-23 and FY 2023-24, there was a 1.9% increase in the number of drug-related charges laid by the RCMP. A total of 6,681 drug-related charges were laid by the RCMP, with 27% (1,794) laid by Federal Policing. Of the 27% (1,794) charges laid by Federal Policing: 80.5% (1,444) were related to trafficking offences; 7.7% (138) were related to possession offences; 5.9% (105) were cannabis-related; 5.7% (102) were related to import/export offences; 0.3% (5) were related to Production offences.

Return to footnote 28 referrer

Footnote 29

Funding for the renewed CDSS came into effect on April 1, 2024, for a select number of positions attributed to the RCMP. The RCMP is presently working through various staffing processes to fill the positions, and commence the work to address the recommendations and planned actions outlined in the Horizontal Initiative.

Return to footnote 29 referrer

Footnote 30

Funding for the renewed CDSS came into effect on April 1, 2024, for a select number of positions attributed to the RCMP. The RCMP is presently working through various staffing processes to fill the positions, and commence the work to address planned actions outlined in the Horizontal Initiative. As such the starting point and target can only be established by March 31, 2025.

Return to footnote 30 referrer

Footnote 31

Criminal Intelligence Service Canada is in the process of staffing intelligence collector positions. Once staffed, CISC will have the capacity to achieve target by March 31, 2025.

Return to footnote 31 referrer

Footnote 32

The RCMP is on track to meet its target by March 31, 2025.

Return to footnote 32 referrer

Footnote 33

24% (160 of 665 occurrences) of RCMP organized crime-related drug occurrences reported during FY2023-24 were transnational.

Return to footnote 33 referrer

Footnote 34

A target of 75% became effective in 2023-24, and was established based on data from 2022-23 survey results following compliance promotion activities with industry stakeholders. This activity was recently launched in 2022-23 and there remains some uncertainty regarding the percentage of stakeholders who will increase their knowledge of regulatory requirements from compliance promotion sessions, in particular as the program expands compliance promotion to other stakeholders such as provincial regulatory authorities who are likely to be more knowledgeable in this domain, and/or to stakeholders who may have previously attended compliance promotion sessions. The program continues to see this activity as successful if 75% or more of stakeholders increase their awareness of regulatory requirements, with some additional stakeholders reinforcing knowledge that they had previously acquired.

Return to footnote 34 referrer

Page details

2024-12-17